High-throughput biophysical analysis and data visualization of conformational stability of an IgG1 monoclonal antibody after deglycosylation.
暂无分享,去创建一个
C Russell Middaugh | David D Weis | Sangeeta B Joshi | Thomas J Tolbert | David B Volkin | S. Joshi | D. Volkin | C. R. Middaugh | D. Weis | Jae Hyun Kim | J. H. Kim | R. Majumdar | Mohammad Alsenaidy | T. Tolbert | Mohammad A Alsenaidy | Ranajoy Majumdar | C. Middaugh
[1] Jihun Lee,et al. An empirical phase diagram approach to investigate conformational stability of “second‐generation” functional mutants of acidic fibroblast growth factor‐1 , 2012, Protein science : a publication of the Protein Society.
[2] R. Ghirlando,et al. Glycosylation of human IgG-Fc: influences on structure revealed by differential scanning micro-calorimetry. , 1999, Immunology letters.
[3] B. Scallon,et al. Glycosylation in the Fc domain of IgG increases resistance to proteolytic cleavage by papain. , 2006, Biochemical and biophysical research communications.
[4] C Russell Middaugh,et al. Comparison of high-throughput biophysical methods to identify stabilizing excipients for a model IgG2 monoclonal antibody: conformational stability and kinetic aggregation measurements. , 2012, Journal of pharmaceutical sciences.
[5] Marcella Yu,et al. Production, characterization and pharmacokinetic properties of antibodies with N-linked Mannose-5 glycans , 2012, mAbs.
[6] G. Gilliland,et al. Structure-based engineering of a monoclonal antibody for improved solubility. , 2010, Protein engineering, design & selection : PEDS.
[7] David Ouellette,et al. Increased serum clearance of oligomannose species present on a human IgG1 molecule , 2012, mAbs.
[8] H. Gadgil,et al. Evaluation of effects of Fc domain high-mannose glycan on antibody stability. , 2012, Journal of pharmaceutical sciences.
[9] David B Volkin,et al. Analytical lessons learned from selected therapeutic protein drug comparability studies. , 2013, Biologicals : journal of the International Association of Biological Standardization.
[10] T. Veenstra,et al. Engineered Human Antibody Constant Domains with Increased Stability* , 2009, Journal of Biological Chemistry.
[11] R. Bayer,et al. The impact of glycosylation on monoclonal antibody conformation and stability , 2011, mAbs.
[12] C Russell Middaugh,et al. Formulation design and high-throughput excipient selection based on structural integrity and conformational stability of dilute and highly concentrated IgG1 monoclonal antibody solutions. , 2012, Journal of pharmaceutical sciences.
[13] Nathaniel R Maddux,et al. An improved methodology for multidimensional high-throughput preformulation characterization of protein conformational stability. , 2012, Journal of pharmaceutical sciences.
[14] G. Litman,et al. Atypical glycosylation of an IgG monoclonal cryoimmunoglobulin. , 1987, The Journal of biological chemistry.
[15] Linda O Narhi,et al. High throughput thermostability screening of monoclonal antibody formulations. , 2010, Journal of pharmaceutical sciences.
[16] Santosh V. Thakkar,et al. Comparison of the structural stability and dynamic properties of recombinant anthrax protective antigen and its 2-fluorohistidine-labeled analogue. , 2012, Journal of pharmaceutical sciences.
[17] P. Bondarenko,et al. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. , 2011, Glycobiology.
[18] C Russell Middaugh,et al. Improved data visualization techniques for analyzing macromolecule structural changes , 2012, Protein science : a publication of the Protein Society.
[19] Bill Pikounis,et al. Comparability assessments of process and product changes made during development of two different monoclonal antibodies. , 2011, Biologicals : journal of the International Association of Biological Standardization.
[20] B. Müller-Tiemann,et al. Generation and Comparative Characterization of Glycosylated and Aglycosylated Human IgG1 Antibodies , 2013, Molecular Biotechnology.
[21] R. Jefferis. Isotype and glycoform selection for antibody therapeutics. , 2012, Archives of biochemistry and biophysics.
[22] Janice M. Reichert,et al. Marketed therapeutic antibodies compendium , 2012, mAbs.
[23] Anthony Mire-Sluis,et al. Characterizing biological products and assessing comparability following manufacturing changes , 2004, Nature Biotechnology.
[24] M Goodall,et al. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. , 2000, Molecular immunology.
[25] Roy Jefferis,et al. Glycosylation as a strategy to improve antibody-based therapeutics , 2009, Nature Reviews Drug Discovery.
[26] C Russell Middaugh,et al. Biophysical characterization and stabilization of the recombinant albumin fusion protein sEphB4-HSA. , 2012, Journal of pharmaceutical sciences.
[27] L. Narhi,et al. Effect of pH, temperature, and salt on the stability of Escherichia coli- and Chinese hamster ovary cell-derived IgG1 Fc. , 2012, Biochemistry.
[28] R. Jefferis. The antibody paradigm: present and future development as a scaffold for biopharmaceutical drugs , 2009, Biotechnology & genetic engineering reviews.
[29] Akira Okazaki,et al. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. , 2007, Glycobiology.
[30] R. Huber,et al. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. , 2003, Journal of molecular biology.
[31] J. Reichert,et al. Development trends for human monoclonal antibody therapeutics , 2010, Nature Reviews Drug Discovery.
[32] M. Schenerman,et al. Comparability testing of a humanized monoclonal antibody (Synagis) to support cell line stability, process validation, and scale-up for manufacturing. , 1999, Biologicals : journal of the International Association of Biological Standardization.
[33] H. Sathish,et al. Effects of salts from the Hofmeister series on the conformational stability, aggregation propensity, and local flexibility of an IgG1 monoclonal antibody. , 2013, Biochemistry.
[34] J. Hochman,et al. Pharmacokinetics of IgG1 monoclonal antibodies produced in humanized Pichia pastoris with specific glycoforms: a comparative study with CHO produced materials. , 2011, Biologicals : journal of the International Association of Biological Standardization.
[35] R. Rustandi,et al. Biochemical and biophysical characterization of humanized IgG1 produced in Pichia pastoris , 2011, mAbs.
[36] C Russell Middaugh,et al. Correlating excipient effects on conformational and storage stability of an IgG1 monoclonal antibody with local dynamics as measured by hydrogen/deuterium-exchange mass spectrometry. , 2013, Journal of pharmaceutical sciences.
[37] Bernhardt L Trout,et al. Aggregation-prone motifs in human immunoglobulin G. , 2009, Journal of molecular biology.
[38] Martin Schiestl,et al. Acceptable changes in quality attributes of glycosylated biopharmaceuticals , 2011, Nature Biotechnology.
[39] R. Jefferis,et al. Interaction sites on human IgG-Fc for FcγR: current models , 2002 .
[40] S. Jung,et al. Revisiting the role of glycosylation in the structure of human IgG Fc. , 2012, ACS chemical biology.
[41] A K Patel,et al. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. , 1995, Molecular immunology.
[42] H. Gadgil,et al. Elucidation of Acid-induced Unfolding and Aggregation of Human Immunoglobulin IgG1 and IgG2 Fc , 2011, The Journal of Biological Chemistry.
[43] Hongcheng Liu,et al. Effect of posttranslational modifications on the thermal stability of a recombinant monoclonal antibody. , 2006, Immunology letters.
[44] B. Scallon,et al. Fc Glycans Terminated with N‐Acetylglucosamine Residues Increase Antibody Resistance to Papain , 2007, Biotechnology progress.
[45] Gregory C Flynn,et al. The effect of Fc glycan forms on human IgG2 antibody clearance in humans. , 2008, Glycobiology.
[46] Hollis Lau,et al. Acid-induced aggregation of human monoclonal IgG1 and IgG2: molecular mechanism and the effect of solution composition. , 2010, Biochemistry.
[47] P. M. Buck,et al. Impact of deglycosylation and thermal stress on conformational stability of a full length murine igG2a monoclonal antibody: Observations from molecular dynamics simulations , 2013, Proteins.
[48] Yow-Ming C Wang,et al. Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies. , 2010, Trends in biotechnology.
[49] S. Berkowitz,et al. Characterization of IgG1 Conformation and Conformational Dynamics by Hydrogen/Deuterium Exchange Mass Spectrometry. , 2009, Analytical chemistry.
[50] Damian Houde,et al. Post-translational Modifications Differentially Affect IgG1 Conformation and Receptor Binding* , 2010, Molecular & Cellular Proteomics.
[51] M. Schenerman,et al. Advances in the assessment and control of the effector functions of therapeutic antibodies , 2011, Nature Reviews Drug Discovery.
[52] S. Radaev,et al. Recognition of IgG by Fcgamma receptor. The role of Fc glycosylation and the binding of peptide inhibitors. , 2001, The Journal of biological chemistry.
[53] Kai Griebenow,et al. Effects of glycosylation on the stability of protein pharmaceuticals. , 2009, Journal of pharmaceutical sciences.
[54] Pauline M Rudd,et al. The impact of glycosylation on the biological function and structure of human immunoglobulins. , 2007, Annual review of immunology.
[55] Daniela Bumbaca,et al. Physiochemical and Biochemical Factors Influencing the Pharmacokinetics of Antibody Therapeutics , 2012, The AAPS Journal.
[56] Comparative signature diagrams to evaluate biophysical data for differences in protein structure across various formulations. , 2013, Journal of pharmaceutical sciences.
[57] Kim Vo,et al. Isolation and characterization of IgG1 with asymmetrical Fc glycosylation. , 2011, Glycobiology.
[58] Bernhardt L Trout,et al. Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies. , 2011, Biotechnology journal.
[59] Wei Wang,et al. Antibody structure, instability, and formulation. , 2007, Journal of pharmaceutical sciences.